PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 17, 2026BioinformaticsOpen Access

Characterizing Clinical Toxicity in Cancer Combination Therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

AWAlexandra M. WongCMCecile Meier-ScherlingLCLorin Crawford

Discussion

Loading...

Member takes

Overview

Examines toxicity and synergy in cancer therapies, highlighting challenges in predicting adverse drug interactions.

Key Points

  • The aim is to explore the correlation between synergy scores and toxicity metrics in cancer drug combinations.
  • Analyzed existing toxicity penalties in computational models.
  • Assessed correlation of synergy scores with known adverse drug interactions.
  • Examined trends in toxicity levels and metrics.
  • Some toxicity metrics showed correlation trends with synergy scores.
  • Significant limitations were found in using toxicity metrics as penalties.
  • Need for more comprehensive combination toxicity data was emphasized.

Cite This Study

Wong et al. (2026) studied this question.

synapsesocial.com/papers/696b26d7d2a12237a934a187https://doi.org/10.1093/bioinformatics/btag007
View Full Paper
Ask AI
Bookmark
Share